Cabaletta Bio Inc. (CABA)
NASDAQ: CABA
· Real-Time Price · USD
1.26
-0.06 (-4.55%)
At close: May 01, 2025, 3:59 PM
1.28
1.55%
After-hours: May 01, 2025, 05:55 PM EDT
-4.55% (1D)
| Bid | 1.25 |
| Market Cap | 63.94M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -115.86M |
| EPS (ttm) | -2.34 |
| PE Ratio (ttm) | -0.54 |
| Forward PE | -0.5 |
| Analyst | Buy |
| Ask | 1.4 |
| Volume | 437,925 |
| Avg. Volume (20D) | 1,028,160 |
| Open | 1.32 |
| Previous Close | 1.32 |
| Day's Range | 1.26 - 1.33 |
| 52-Week Range | 0.99 - 13.50 |
| Beta | 2.44 |
About CABA
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART,...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 25, 2019
Employees 161
Stock Exchange NASDAQ
Ticker Symbol CABA
Website https://www.cabalettabio.com
Analyst Forecast
According to 8 analyst ratings, the average rating for CABA stock is "Buy." The 12-month stock price forecast is $22.5, which is an increase of 1685.71% from the latest price.
Stock Forecasts5 months ago
-19.84%
Cabaletta Bio shares are trading lower after Wells...
Unlock content with
Pro Subscription
8 months ago
-34.37%
Cabaletta Bio shares are trading lower. The company reported Q2 financial results.
